USRE29077EExpiredUtility

Tablet formulation

Priority: Dec 6, 1972Filed: Mar 15, 1976Granted: Dec 14, 1976
Est. expiryDec 6, 1992(expired)· nominal 20-yr term from priority
A61K 9/2072A61J 3/10
31
PatentIndex Score
12
Cited by
13
References
5
Claims

Abstract

The disclosure is directed to formulations for tablets which are to be deeply grooved to facilitate breaking into predetermined portions by the user. A critical tablet weight for deeply grooved tablets is disclosed.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A pharmaceutical tablet which is adequately imprinted with indicia or embossing and scored to form a groove which is one-third to two-thirds the depth of the total tablet thickness to facilitate separation into subdivisions containing substantially equal amounts of a pharmaceutically active ingredient comprising a directly compressed formulation of 5 to 10 milligrams of an active ingredient, the remainder being 45 to 99.7 percent by weight of microcrystalline cellulose and 0.3 to 0.4 percent by weight of magnesium stearate, along with fillers, extenders, flavoring and the like. 
     
     
       2. The tablet as defined in claim 1 in which the total tablet weight is 150 to 175 milligrams. 
     
     
       3. A tablet as defined in claim 1 in which the total tablet weight is about 175 milligrams. 
     
     
       4. A tablet as defined in claim 1 in which the microcrystalline cellulose is present in the amount of 60 percent by weight and the magnesium stearate is present in the amount of 0.35 percent by weight. 
     
     
       5. A tablet as defined in claim 1 in which the active ingredient is 5 to 10 milligrams of isosorbide dinitrate. .Iadd. 6. A pharmaceutical tablet which is adequately imprinted with indicia or embossing and scored to form a groove which is one-third to two-thirds the depth of the total thickness to facilitate separation into subdivisions containing substantially equal amounts of a pharmaceutically active ingredient comprising a directly compressed formulation of an effective amount of an active ingredient, the remainder being 45 to 99.7 percent by weight of microcrystalline cellulose and 0.3 to 0.4 percent by weight of magnesium stearate, along with fillers, extenders, flavoring and the like. .Iaddend.

Join the waitlist — get patent alerts

Track USRE29077E — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.